Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-109 in unresectable or metastatic conventional chondrosarcoma
2024-517528-20-00Phase 2Authorised
- Sponsor
- Inhibrx Biosciences
- Start
- Oct 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in conventional chondrosarcoma comparing Ozekibart (INBRX-109) with Placebo (2 arms). Primary endpoint: Progression-free survival (PFS) by central IRR. Planned start Oct 2024; status: authorised.
02
Drugs
ozekibart
03
Conditions
conventional chondrosarcoma
Beyond the preview
Go deeper on 2024-517528-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517528-20-00.